Notice: This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. ACAD, MOR, XENE, AMRX, BHC, FOLD, NAMS, HCM, MLTX, and MIRMShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), MoonLake Immunotherapeutics (MLTX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "medical" sector. Cerecor vs. ACADIA Pharmaceuticals MorphoSys Xenon Pharmaceuticals Amneal Pharmaceuticals Bausch Health Companies Amicus Therapeutics NewAmsterdam Pharma HUTCHMED MoonLake Immunotherapeutics Mirum Pharmaceuticals Cerecor (NASDAQ:CERC) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation. Is CERC or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Cerecor's net margin of -1,194.82%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Cerecor's return on equity.Company Net Margins Return on Equity Return on Assets Cerecor-1,194.82% -261.82% -133.96% ACADIA Pharmaceuticals 13.83%25.83%14.71% Which has more risk & volatility, CERC or ACAD? Cerecor has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Do institutionals & insiders hold more shares of CERC or ACAD? 62.8% of Cerecor shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 45.7% of Cerecor shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, CERC or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Cerecor. Cerecor is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerecor$6.70M121.23-$63.50M-$0.57-14.84ACADIA Pharmaceuticals$957.80M2.88-$61.29M$1.3612.18 Does the media prefer CERC or ACAD? In the previous week, ACADIA Pharmaceuticals had 13 more articles in the media than Cerecor. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 0 mentions for Cerecor. ACADIA Pharmaceuticals' average media sentiment score of 0.87 beat Cerecor's score of 0.16 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Cerecor Neutral ACADIA Pharmaceuticals Positive Does the MarketBeat Community favor CERC or ACAD? ACADIA Pharmaceuticals received 712 more outperform votes than Cerecor when rated by MarketBeat users. However, 74.00% of users gave Cerecor an outperform vote while only 73.05% of users gave ACADIA Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCerecorOutperform Votes18574.00% Underperform Votes6526.00% ACADIA PharmaceuticalsOutperform Votes89773.05% Underperform Votes33126.95% Do analysts recommend CERC or ACAD? ACADIA Pharmaceuticals has a consensus price target of $23.93, indicating a potential upside of 44.48%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Cerecor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerecor 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ACADIA Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryACADIA Pharmaceuticals beats Cerecor on 14 of the 18 factors compared between the two stocks. Remove Ads Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$812.24M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-14.847.3523.5018.55Price / Sales121.23208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book38.456.256.814.11Net Income-$63.50M$142.34M$3.20B$247.18M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$8.46-3.1%N/A-61.1%$812.24M$6.70M-14.8431ACADACADIA Pharmaceuticals4.1424 of 5 stars$17.23+2.6%$23.93+38.9%-7.7%$2.87B$957.80M22.09510Gap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsXENEXenon Pharmaceuticals2.4465 of 5 stars$36.45+3.1%$57.38+57.4%-20.4%$2.79B$9.43M-12.93210Analyst UpgradeNews CoveragePositive NewsAMRXAmneal Pharmaceuticals3.2668 of 5 stars$8.89+2.7%$10.80+21.5%+36.6%$2.76B$2.79B-13.077,600Positive NewsBHCBausch Health Companies3.9547 of 5 stars$7.27+1.5%$7.42+2.1%-38.9%$2.67B$9.63B-60.5419,900FOLDAmicus Therapeutics4.0679 of 5 stars$8.69-3.6%$16.75+92.8%-28.4%$2.67B$528.30M-48.28480High Trading VolumeNAMSNewAmsterdam Pharma2.4518 of 5 stars$24.00+0.5%$43.33+80.6%-8.0%$2.64B$45.56M-9.234Short Interest ↑News CoveragePositive NewsGap UpHCMHUTCHMED2.6912 of 5 stars$15.09+0.7%$19.00+25.9%-9.2%$2.63B$630.20M0.001,988MLTXMoonLake Immunotherapeutics2.2103 of 5 stars$40.58+1.1%$80.50+98.4%-20.6%$2.60BN/A-31.462MIRMMirum Pharmaceuticals4.3747 of 5 stars$47.02flat$58.20+23.8%+83.1%$2.30B$336.89M-23.28140News CoveragePositive News Remove Ads Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives MorphoSys Alternatives Xenon Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Bausch Health Companies Alternatives Amicus Therapeutics Alternatives NewAmsterdam Pharma Alternatives HUTCHMED Alternatives MoonLake Immunotherapeutics Alternatives Mirum Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
